Muntoni, Francesco
Fletcher, Sue
Wilton, Steve
Article History
First Online: 7 March 2017
Change Date: 30 March 2017
Change Type: Corrigendum
Change Details: In the version of this article initially published, F.M. was credited for giving input on study design and data analysis, which he did not. The error has been corrected in the HTML and PDF versions of the article.
Competing interests
: F.M. was involved in the original investigator-led and independently funded phase 1 and 2A studies that led to the development of Exondys 51. F.M. has received consulting fees from PTC Therapeutics, Sarepta Therapeutics, BioMarin, Roche, Biogen, Italfarmaco, Avexis, Pfizer, Trivorsan, Catabasis and Wave Therapeutics. S.F. and S.W. are named inventors on patents describing Exondys 51 and other exon skipping compounds, which are licensed to Sarepta Therapeutics by the University of Western Australia. S.F and S.W. are consultants to Sarepta Therapeutics.